|
|
SPOT ON
|
|
ACCORD study - treatment guidelines for type 2 diabetes on trial
|
|
|
NEW ON THE MARKET
|
|
Pneumococcal vaccines PREVENAR 13, SYNFLORIX
|
|
|
READERS' QUESTIONS AND COMMENTS
|
|
Bipolar disorder: avoidable turnaround of EMA
|
|
|
THERAPY FROM A CRITICAL VIEWPOINT
|
|
Diabetes prevention study NAVIGATOR
|
|
|
IN BRIEF
|
|
Quality tests of oxycodone preparations
Recall of clopidogrel generics of Indian origin
|
|
Contamination of rota virus vaccine: avoid ROTARIX
Contraindication: Becaplermin (REGRANEX) and cancer
|
|
|
CURRENT ADR NETWORK REPORT
|
|
Uzara root extract (UZARA) and facial oedema
|
|
|
SIDE EFFECTS
|
|
Fatal renal failure due to bisphosphonate zoledronate
Non-prescription orlistat (ALLI): first establish on the market, then warn
|
|